Become a client

Are you a client? You should contact your private banker. 
You are not a client but would like to have more information about Societe Generale Private Banking? Please fill in the form below.

Local contacts

France: +33 (0)1 53 43 87 00 (9am - 6pm)
Luxembourg: +352 47 93 11 1 (8:30am - 5:30pm)
Monaco: +377 97 97 58 00 (9/12am - 2/5pm)
Switzerland: Geneva +41 22 819 02 02
& Zurich +41 44 218 56 11 (8:30am - 5:30pm)

You would like to contact us about the protection of your personal data?

Please contact the Data Protection Officer of Societe Generale Private Banking France by sending an email to the following address: protectiondesdonnees@societegenerale.fr.

Please contact the Data Protection Officer of Societe Generale Luxembourg by sending an email to the following address: lux.dpooffice@socgen.com.

For customers residing in Italy, please contact BDO, the external provider in charge of Data Protection, by sending an email to the following address: lux.dpooffice-branch-IT@socgen.com

Please contact the Data Protection Officer of Societe Generale Private Banking Monaco by sending an email to the following address: list.mon-privmonaco-dpo@socgen.com

Please contact the Data Protection Officer of Societe Generale Private Banking Switzerland by sending an email to the following address : ch-dataprotection@socgen.com

You need to make a claim?

Societe Generale Private Banking aims to provide you with the best possible quality of service. However, difficulties may sometimes arise in the operation of your account or in the use of the services made available to you.

Your private banker  is your privileged contact to receive and process your claim.

 If you disagree with or do not get a response from your advisor, you can send your claim to the direction  of Societe Generale Private Banking France by email to the following address: FR-SGPB-Relations-Clients@socgen.com or by mail to: 

Société Générale Private Banking France
29 boulevard Haussmann CS 614
75421 Paris Cedex 9

Societe Generale Private Banking France undertakes to acknowledge receipt of your claim within 10 (ten) working days from the date it is sent and to provide you with a response within 2 (two) months from the same date. If we are unable to meet this 2 (two) month deadline, you will be informed by letter.

In the event of disagreement with the bank  or of a lack of response from us within 2 (two) months of sending your first written claim, or within 15 (fifteen) working days for a claim about a payment service, you may refer the matter free of charge, depending on the nature of your claim, to:  

 

The Consumer Ombudsman at the FBF

The Consumer Ombudsman at the Fédération Bancaire Française (FBF – French Banking Federation) is competent for disputes relating to services provided and contracts concluded in the field of banking operations (e.g. management of deposit accounts, credit operations, payment services etc.), investment services, financial instruments and savings products, as well as the marketing of insurance contracts.

The FBF Ombudsman will reply directly to you within 90 (ninety) days from the date on which she/he receives all the documents on which the request is based. In the event of a complex dispute, this period may be extended. The FBF Ombudsman will formulate a reasoned position and submit it to both parties for approval.

The FBF Ombudsman can be contacted on the following website: www.lemediateur.fbf.fr or by mail at:

Le Médiateur de la Fédération Bancaire Française
CS 151
75422 Paris CEDEX 09

 

The Ombudsman of the AMF

The Ombudsman of the Autorité des Marchés Financiers (AMF - French Financial Markets Authority) is also competent for disputes relating to investment services, financial instruments and financial savings products.

For this type of dispute, as a consumer customer, you have therefore a choice between the FBF Ombudsman and the AMF Ombudsman. Once you have chosen one of these two ombudsmen, you can no longer refer the same dispute to the other ombudsman.

The AMF Ombudsman can be contacted on the AMF website: www.amf-france.org/fr/le-mediateur or by mail at:

Médiateur de l'AMF, Autorité des Marchés Financiers
17 place de la Bourse
75082 PARIS CEDEX 02
FRANCE


The Insurance Ombudsman

The Insurance Ombudsman is competent for disputes concerning the subscription, application or interpretation of insurance contracts.

The Insurance Ombudsman can be contacted using the contact details that must be mentioned in your insurance contract.

To ensure that your requests are handled effectively, any claim addressed to Societe Generale Luxembourg should be sent to:

Private banking Claims department
11, Avenue Emile Reuter
L-2420 Luxembourg

Or by email to clienteleprivee.sglux@socgen.com and for customers residing in Italy at societegenerale@unapec.it

The Bank will acknowledge your request within 10 working days and provide a response to your claim within 30 working days of receipt. If your request requires additional processing time (e.g. if it involves complex research), the Bank will inform you of this situation within the same 30-working day timeframe.

In the event that the response you receive does not meet your expectations, we suggest the following:

Initially, you may wish to contact the Societe Generale Luxembourg Division responsible for handling claims, at the following address:

Corporate Secretariat of Societe Generale Luxembourg
11, Avenue Emile Reuter
L-2420 Luxembourg

If the response from the Division responsible for claims does not resolve the claim, you may wish to contact Societe Generale Luxembourg's supervisory authority, the “Commission de Surveillance du Secteur Financier”/“CSSF” (Luxembourg Financial Sector Supervisory Commission):

By mail: 283, Route d’Arlon L-1150 Luxembourg
By email:
direction@cssf.lu

Any claim addressed to Societe Generale Private Banking Monaco should be sent by e-mail to the following address: servicequalite.privmonaco@socgen.com or by mail to our dedicated department: 

Societe Generale Private Banking Monaco
Middle Office – Service Réclamation 
11 avenue de Grande Bretagne
98000 Monaco

The Bank will acknowledge your request within 2 working days after receipt and provide a response to your claim within a maximum of 30 working days of receipt. If your request requires additional processing time (e.g. if it involves complex researches…), the Bank will inform you of this situation within the same 30-working day timeframe. 

In the event that the response you receive does not meet your expectations, we suggest to contact the Societe Generale Private Banking Direction that handles the claims by mail at the following address: 

Societe Generale Private Banking Monaco
Secrétariat Général
11 avenue de Grande Bretagne 
98000 Monaco

Any claim addressed to the Bank can be sent by email to:

sgpb-reclamations.ch@socgen.com
 

Clients may also contact the Swiss Banking Ombudsman: 

www.bankingombudsman.ch

 

Interview with Michel Feraud, President of Provepharm

A researcher who wants to find himself

Michel Feraud was a young student of organic chemistry at the Université Saint-Jérôme in Marseilles when it clicked: “I considered chemistry to be like Lego® where molecules could be transformed into medicines to cure.” In 1997, armed with their doctorates, Michel Feraud and his childhood friend, Christophe Baralotto, decided to start their company — without capital — which would in time become Provepharm Life Solutions. “Even if we had no idea what we were going to do, we knew exactly where we were going to do it, that is, all over the world.”

 

Controlled risk-taking

The company began by offering its services to other laboratories such as L'Oréal, Johnson & Johnson and even Aventis. At the same time, it looked to investors, while ensuring that its shareholders remained independent. “We financed, for example, through convertible bonds*, contrary to the practices of the time. We therefore managed to preserve the majority of our capital." In 2018, the Tethys fund of the Bettencourt family and ArchiMed — the first independent European funds dedicated to this sector — also contributed to the capital. And Michel Feraud and Christophe Baralotto still hold 67% of the shares.

(*) Type of bonds offering a right of conversion into shares.

Reinventing methylene blue

In 2007, Provepharm Life Solutions reinvented a decidedly vintage remedy, methylene blue. The molecule, discovered in 1876, has many antiseptic and antioxidant qualities.
But, because it contains some potentially toxic heavy metals, its therapeutic use has been progressively phased out and banned. By patenting a process that eliminates these heavy metals, the company re-created methylene blue under the name Provayblue®, and with it, developed a new antidote against severe blood poisoning. In country after country, the national drug agencies gave marketing authorisation for this regenerated molecule. “It all started with France in 2010, and today we have a presence in nearly 35 countries.” The most recent marketing authorisations were obtained in the United States.

“In 2016, we secured a sevenyear agreement for the exclusive commercialisation of Provayblue® by obtaining an orphan drug designation. As a responsible company, this agreement requires us to ensure that products are always available throughout the United States — which is normal. For this purpose, we have a strategic stock of 200,000 units in the United States. That represents a six months’ treatment supply, proof that we are 100% patient oriented. It is unthinkable that someone has to do without their therapy because a laboratory has not been able to manage their supply chain or, much worse, has made unreasonable profits through financial arbitrage.”

 

Innovation at the heart of company philosophy

If Provepharm Life Solutions' R&D teams are doing so well, it's probably because shareholders and management give them time to work their magic. “At Provepharm Life Solutions, we have a real desire to encourage the entrepreneur within all our employees. In a world in search of purpose, we want to give meaning to intelligence and, above all, we want to avoid sheep-like behaviour. I am convinced that companies need to carry a core message with them. Ours is that there is a third way between biotechs and generic specialists, i.e. reinventing molecules with prior therapeutic virtues, making them compatible with the very strict specifications of modern health agencies.”

€42.5 million to accelerate growth

The creation of a new 3,000 m2 production unit in Marseilles, an investment of €9 million and the establishment of a new subsidiary in the United States are all signs that underline the fast-paced development of Provepharm Life Solutions.
Its turnover increased by 27% in one year to €38 million by the end of 2018. To support its new projects, the company has just obtained a syndicated credit* of €42.5 million.

 

From research against malaria to committed social responsibility

Among other ongoing research, Provepharm Life Solutions is working on a treatment for malaria, that is already supported by the US Army. Size is certainly an issue.
According to WHO, this disease killed 429,000 people in 2015, with nearly 212 million recorded cases worldwide. Their strategy? No Gain, No Loss. “We are not driven by earnings, but we do not want to lose money either.” To speed up its R&D, the company therefore relies on nurturing the talents of their employees, an international cast hailing from over ten different countries, worldwide. At the same time, diversity is particularly close to their hearts. For example, women make up the majority of the workforce and three women sit on the board of directors. To conclude this interview, Michel Feraud also wished to mention one of the key factors of his success.
“Regardless of a person's profession or their sector of activity, I think it's important to dare to use common sense. This third way is full of opportunities for both business and people. And above all, it creates societal value that can be shared by all.” In this area, Michel certainly knows what he is talking about.

(*) Loan granted by several banks to the same company.